附子理中丸在慢性束缚应激小鼠中经系统药理学产生抗抑郁样作用
本研究旨在验证附子理中丸(FLP)在慢性束缚应激(CRS)小鼠中的抗抑郁样效应并探索分子机制。通过网络药理学、UHPLC-MS/MS、分子对接及多种实验方法,发现FLP的抗抑郁样作用涉及激活PI3K/Akt/mTOR通路、抑制MAPK通路、减轻炎症及改善肠道菌群失调。
要点
- FLP在CRS小鼠中显著减少强迫游泳和悬尾实验的不动时间,提高糖水偏好。
- FLP上调BDNF-TrkB和PI3K/Akt/mTOR通路蛋白,下调MAPK通路蛋白。
- FLP降低血清CORT、IL-6、IL-1β、TNF-α,并改善肠道菌群失调和神经损伤。
核心结论
- FLP在CRS小鼠中具有抗抑郁样效应,机制涉及激活PI3K/Akt/mTOR通路、增加树突棘生成、抑制MAPK通路、减轻炎症及改善肠道菌群失调。
研究设计与样本
- 采用CRS诱导的小鼠抑郁模型,结合网络药理学预测、UHPLC-MS/MS成分检测、分子对接及western blotting、ELISA、16S rRNA测序、HE染色、Nissl染色和Golgi-Cox染色等实验验证。
主要发现
- 网络药理学和UHPLC-MS/MS分析表明FLP的活性成分包括taraxerol、songorine、neokadsuranic acid B、ginkgetin、hispaglabridin B、quercetin、benzoylmesaconine和liquiritin。
- KEGG通路分析提示PI3K/Akt/mTOR和MAPK信号通路与FLP的抗抑郁效应密切相关,分子对接显示主要成分与PI3K、AKT、mTOR、BDNF和MAPK结合。
- FLP显著降低CRS小鼠在FST和TST中的不动时间,显著提高SPT中的糖水偏好。
- FLP上调BDNF-TrkB和PI3K/Akt/mTOR通路相关蛋白,下调MAPK通路相关蛋白,并显著降低血清CORT、IL-6、IL-1β和TNF-α水平。
- FLP改善CRS诱导的肠道菌群失调、肠道炎症和神经元损伤,且雷帕霉素处理后FLP的抗抑郁样效应及树突棘密度增加被减弱。
临床怎么用
- 本研究为动物实验,结果提示FLP可能通过多靶点机制发挥抗抑郁作用,为临床应用于抑郁症提供了新证据,但临床用药需结合辨证并参考后续临床研究。
局限性
- 研究仅在小鼠模型中进行,尚未在人体中验证FLP的抗抑郁疗效及安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Fuzi-Lizhong pill (FLP) is a well-validated traditional Chinese medicine (TCM) formula that has long been used in China for gastrointestinal disease and adjunctive therapy for depression. In our previous study, we reported that the principal herb of FLP, Aconitum carmichaelii Debx. (Fuzi), exhibits antidepressant-like effects. However, there have been no reports on whether FLP produces antidepressant-like effects and its potential molecular mechanisms. AIM OF THE STUDY: We aim to demonstrate the antidepressant-like effects of FLP in chronic restraint stress (CRS) mice and to explore the associated molecular mechanisms. MATERIALS AND METHODS: The active components and probable molecular targets of FLP, as well as the targets related to depression, were identified through network pharmacology. A protein-protein interaction (PPI) network was generated using the overlapping targets, followed by the visualization as well as identification of the core targets associated with the antidepressant-like action of FLP. Subsequently, KEGG and GO enrichment analyses were conducted. UHPLC-MS/MS was employed to further detect the active compounds in FLP. Molecular docking was applied to assess the connections between the active components as well as the core targets. The efficacy of FLP in treating depression and its molecular mechanisms were examined using western blotting, ELISA, 16S rRNA sequencing, HE staining, Nissl staining, and Golgi-Cox staining in a CRS-induced mouse model. RESULTS: Network pharmacology and UHPLC-MS/MS analyses indicated that the active compounds of FLP comprised taraxerol, songorine, neokadsuranic acid B, ginkgetin, hispaglabridin B, quercetin, benzoylmesaconine and liquiritin. KEGG pathway analysis implicated that the PI3K/Akt/mTOR as well as MAPK signaling pathways are closely related to the therapeutic effects of FLP on depression. Molecular docking analysis demonstrated that the main components of FLP bind to PI3K, AKT, mTOR, BDNF and MAPK. FLP significantly decreased immobility in mice that were elevated by CRS in the FST and the TST. FLP also significantly increased sucrose preference in mice after CRS in the SPT. FLP upregulated proteins associated with BDNF-TrkB and PI3K/Akt/mTOR signaling and downregulated proteins associated with MAPK signaling. Serum levels of CORT, IL-6, IL-1β, and TNF-α in CRS mice were significantly decreased following treatment with FLP. In addition, FLP ameliorated CRS-induced gut microbiota dysbiosis as demonstrated by 16S rRNA sequencing analysis. FLP ameliorated CRS-induced intestinal inflammation and neuronal damage. Finally, antidepressant-like effects and concomitant increases in dendritic spine density induced by FLP administration were also reduced after rapamycin treatment. CONCLUSION: These results demonstrate that FLP has antidepressant-like effects in mice exposed to CRS that involve activation of the PI3K/Akt/mTOR signaling pathway, increase in spinogenesis, inhibition of the MAPK signaling pathway, decrease in inflammation, and amelioration of gut microbiota dysbiosis. These findings provide novel evidence for the clinical application of FLP on depression.
引用
- Zhao F, Piao J, Song J, et al. Traditional Chinese herbal formula, Fuzi-Lizhong pill, produces antidepressant-like effects in chronic restraint stress mice through systemic pharmacology. J Ethnopharmacol. 2024. PMID: 39486672. doi:10.1016/j.jep.2024.119011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。